Vanguard Group Inc Surface Oncology, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.62 - $1.21 $505 - $987	816 Added 0.04%	2,309,286 $1.89 Million
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.1 $533,494 - $1.07 Million	508,090 Added 28.22%	2,308,470 $2.4 Million
Q2 2022 Aug 12, 2022	BUY	$1.42 - $3.15 $396,715 - $880,037	279,377 Added 18.37%	1,800,380 $2.95 Million
Q1 2022 May 13, 2022	BUY	$2.65 - $5.08 $161,909 - $310,377	61,098 Added 4.19%	1,521,003 $4.47 Million
Q4 2021 Feb 14, 2022	BUY	$4.73 - $7.9 $1.19 Million - $1.98 Million	250,684 Added 20.73%	1,459,905 $6.98 Million
Q3 2021 Nov 12, 2021	BUY	$5.16 - $7.98 $71,151 - $110,036	13,789 Added 1.15%	1,209,221 $9.15 Million
Q2 2021 Aug 13, 2021	BUY	$6.45 - $9.09 $7.71 Million - $10.9 Million	1,195,432 New	1,195,432 $8.92 Million

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.